Back to Search
Start Over
Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
- Source :
- Medicine
- Publication Year :
- 2016
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2016.
-
Abstract
- This study aimed to evaluate the prognostic value of plasma Epstein–Barr Virus DNA (EBV DNA) for local and regionally advanced nasopharyngeal carcinoma (NPC) patients treated with concurrent chemoradiotherapy in intensity-modulated radiotherapy (IMRT) era. In this observational study, 404 nonmetastatic local and regionally advanced NPC patients treated with IMRT and cisplatin-based concurrent chemotherapy were recruited. Blood samples were collected before treatment for examination of plasma EBV DNA levels. We evaluated the association of pretreatment plasma EBV DNA levels with progression-free survival rate (PFS), distant metastasis-free survival rate (DMFS), and overall survival rate (OS). Compared to patients with an EBV DNA level
- Subjects :
- Adult
Male
0301 basic medicine
Herpesvirus 4, Human
medicine.medical_specialty
Pathology
medicine.medical_treatment
Nasopharyngeal neoplasm
Observational Study
Antineoplastic Agents
Gastroenterology
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Predictive Value of Tests
Internal medicine
Carcinoma
Humans
Medicine
Survival rate
Cisplatin
Nasopharyngeal Carcinoma
business.industry
Nasopharyngeal Neoplasms
Chemoradiotherapy
General Medicine
Middle Aged
Prognosis
medicine.disease
Survival Rate
Radiation therapy
Regimen
030104 developmental biology
Nasopharyngeal carcinoma
030220 oncology & carcinogenesis
DNA, Viral
Female
Radiotherapy, Intensity-Modulated
business
Research Article
medicine.drug
Subjects
Details
- ISSN :
- 00257974
- Volume :
- 95
- Database :
- OpenAIRE
- Journal :
- Medicine
- Accession number :
- edsair.doi.dedup.....f1cf47af57f398c10816f258d84675d8